German biochemical SME supplying diagnostic reagents, reference materials, and validated protocols for plant pathogen detection across Europe.
Loewe Biochemica is a German biochemical SME that develops and supplies diagnostic reagents, reference materials, and testing kits for detecting plant pathogens. Their H2020 participation reveals a company with hands-on expertise in laboratory-level identification of quarantine pests — including bacteria such as Xylella fastidiosa and Ca. Liberibacter solanacearum, and fungal threats like Hymenoscyphus and Phytophthora — that devastate European crops and forests. Beyond pathogen work, they have direct experience in building validated diagnostic protocols and proficiency testing frameworks used by plant health laboratories across Europe. In EU consortia they play the role of a specialist supplier and technical contributor, bringing commercial diagnostic product expertise into research settings.
Both POnTE and VALITEST projects centre on detection and identification of plant pests, with Loewe's biochemical product background directly supporting reagent and kit supply in these consortia.
VALITEST (2018–2021) explicitly targeted validation of diagnostic tests and validated protocols, including test performance studies and proficiency testing schemes.
VALITEST keywords include 'reference material' and 'proficiency', indicating Loewe contributed to or supplied certified reference standards used by participating labs.
NGS appears as a keyword in VALITEST, suggesting Loewe engaged with molecular sequencing-based detection methods alongside their classical diagnostic work.
POnTE (2015–2019) addressed five of Europe's highest-priority quarantine pest organisms across olive, potato, and forest ecosystems, with Loewe receiving EUR 118,600 for their contribution.
In their first H2020 project (POnTE, 2015–2019), Loewe's work was anchored in specific threat organisms — Xylella fastidiosa, Ca. Liberibacter solanacearum, Hymenoscyphus, Chalara, Phytophthora — with a clear focus on characterizing what these pathogens do to olives, potatoes, and forests. By their second project (VALITEST, 2018–2021), the language had shifted entirely: the emphasis moved to how we detect and validate that detection — test performance studies, validated protocols, reference materials, proficiency schemes, and NGS methods. This is a meaningful transition from pathogen biology toward quality assurance and diagnostic infrastructure, which is a natural progression for a commercial biochemical supplier moving up the value chain.
Loewe is moving toward becoming a provider of validated diagnostic standards and reference materials — the quality assurance layer of plant health testing — which aligns with growing EU regulatory requirements under the 2019 Plant Health Regulation.
Loewe has participated exclusively as a consortium member, never as a project coordinator, across both H2020 projects. Despite their small size, they have built connections with 38 distinct partners across 16 countries — a notably broad network for a two-project SME, suggesting they bring something concrete enough (reagents, reference materials, validation expertise) that large consortia consistently seek them out. Their profile is that of a specialist contributor who slots into research consortia to provide the commercial and technical diagnostics infrastructure that academic partners cannot supply themselves.
Loewe has worked with 38 unique consortium partners across 16 countries from just two projects, indicating they operate in large, pan-European research networks rather than small bilateral collaborations. Their geographic exposure spans well beyond Germany, though all activity falls within the EU H2020 framework.
Loewe Biochemica occupies a rare position at the intersection of commercial biochemical production and EU-funded plant health research: they are a private, profit-driven SME that has earned a seat in major regulatory science consortia alongside universities and national plant health institutes. This means they can translate research-grade detection methods into commercially available diagnostic products faster than academic partners. For a consortium builder, Loewe adds the practical dimension — reference materials, validated kits, proficiency schemes — that keeps research outputs from staying on paper.
